CRPC w/ Bone Metastases

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. May 17, 2018

Radiation for Treatment of Painful Bone Metastases. May 15, 2018

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. March 20, 2018

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. March 20, 2018

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. March 14, 2018

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. March 14, 2018

Radium-223 international early access program: results from the Spanish subset. March 14, 2018

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223. March 14, 2018

Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. March 12, 2018

Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test Expands Offering to Prostate Cancer Patients - Predicting Treatment Response in Metastatic Disease February 26, 2018

Current approaches to incorporation of radium-223 in clinical practice. January 9, 2018

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer January 8, 2018

Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. January 8, 2018

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. October 1, 2017

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. September 18, 2017

Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity. September 6, 2017

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. September 6, 2017

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. July 15, 2017

Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. May 31, 2017

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. May 1, 2017

Page 1 of 9